CareLit · DOI-Nachweis · Zeitschrift für Gastroenterologie
Efficacy and safety of mirikizumab as induction and maintenance therapy in patients with moderately to severely active Crohn’s disease: Summary results from the Phase 3 VIVID-1 trial
DOI 10.1055/s-0044-1789692
Bibliografische Angaben
Nachweis in CareLit
Autor:innenB. Siegmund, M. Ferrante, V. Jairath, G. D’Haens, S. Maier, M. Protic, W. Crandall, H. Carlier, N. Morris, S. Zeissig
ZeitschriftZeitschrift für Gastroenterologie
Ausgabe09/2024
Jahrgang / SeitenJg. 62 · S. e596-e597
Kernaussage aus der Literatur
Abstract-Vorschau
Efficacy and safety of mirikizumab as induction and maintenance therapy in patients with moderately to severely active Crohn’s disease: Summary results from the Phase 3 VIVID-1 trial
Zitieren
Zitierempfehlung
B. Siegmund, M. Ferrante, V. Jairath, G. D’Haens, S. Maier, M. Protic, W. Crandall, H. Carlier, N. Morris, S. Zeissig (2024) Efficacy and safety of mirikizumab as induction and maintenance therapy in patients with moderately to severely active Crohn’s disease: Summary results from the Phase 3 VIVID-1 trial. Zeitschrift für Gastroenterologie, 62 (09), e596-e597. https://doi.org/10.1055/s-0044-1789692
Mit CareLit weiterarbeiten